Hyperbaric Oxygen Therapy for Diabetic Lower-Limb Wounds in the Caribbean: A Retrospective Cohort Study

Hyperbaric oxygen therapy (HBOT) is an established adjunctive treatment for selected diabetic foot ulcers, although evidence regarding its effectiveness remains heterogeneous. We conducted a retrospective, single-center, observational study of adult diabetic patients receiving HBOT (2.5 ATA, 100% oxygen) for a lower-limb wound at the only hyperbaric center in Guadeloupe, a French Caribbean territory, between January 2020 and June 2023. Among 257 patients treated with HBOT, 71 diabetic patients met inclusion criteria (mean age 63.1 ± 12.7 years; 69% male). Peripheral arterial disease and osteitis were highly prevalent, while the proportion of current smokers (7.9%) was notably lower than in previously published HBOT cohorts, a distinctive feature of this population. HBOT was considered a last resort, after failure of prolonged conventional therapy, in 63% of patients, likely contributing to the modest six-month healing rate of 34% (18/53 evaluable patients) and 19% rate of major amputation occurring during or after HBOT. Patients referred through the multidisciplinary Diabetic Foot Care Unit had fewer major amputations despite older age and greater vascular burden, though this comparison may reflect referral-related selection bias. No candidate factor, including glycemic control, referral pathway, or delay to HBOT, reached statistical significance in univariable analysis. This descriptive, single-arm finding cannot establish HBOT efficacy but is consistent with a role for HBOT within coordinated multidisciplinary diabetic foot care, highlighting the importance of earlier referral and optimised patient selection.